By: Emily Brill From: ajmc.com A new report suggests that much remains to be seen about tissue-agnostic therapies’ effectiveness for treating breast cancer, as “a paucity of data” exists regarding this relatively new treatment’s impact on the disease, and that additional studies are needed to evaluate how well these therapies work on treating metastatic breast cancer (mBC). The investigators reviewed …
Clinical trial demonstrates focused ultrasound can deliver antibody therapy to breast cancer metastases in the brain
By: Focused Ultrasound Foundation From: medicalxpress.com In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain. In this Phase I clinical trial for Her2-positive breast cancer patients, the Sunnybrook team captured …
USC Opens Phase II Trial of Ambrx’s ARX788 for HER2-Positive Breast Cancer
From: precisiononcologynews.com The University of Southern California’s Norris Comprehensive Cancer Center on Monday said it has opened a Phase II trial of Ambrx’s antibody-drug conjugate ARX788 for advanced HER2-positive breast cancer patients. The trial, which is sponsored by La Jolla, California-based Ambrx, will involve roughly 200 HER2-positive metastatic breast cancer patients who have previously received trastuzumab emtansine (Genentech’s Kadcyla; T-DM1), …
Researchers Discover New Molecule That Eliminates Breast Cancer
By: Ty & Charlene Bollinger From: thetruthaboutcancer.com Each year, over 250,000 women (and nearly 2500 men) are diagnosed with breast cancer in the United States. 1 in 8 women will be diagnosed with invasive breast cancer in their lifetime. Approximately three-quarters of cases are a type called estrogen receptor-positive, in which the cancer cells have a receptor in their membranes …
Investigators Combine Zanidatamab With Evorpacept to Potentially Improve Outcomes in HER2-Expressing Breast Cancer
By: Nichole Tucker From: targetedonc.com Zanidatamab in combination with evorpacept has been dosed for the first time in a patient with HER2-low breast cancer. The first patient has been dosed with the combination of zanidatamab and evorpacept (ALX148) in a phase 1b/2 study evaluating the safety and efficacy of the combination in HER2-low breast cancer, and additional non-breast HER2-expressing solid …
Team discovers novel strategy to tame aggressive breast cancer and starts clinical trial
By: National Cancer Centre Singapore From: medicalxpress.com A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less …
Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients
From: prnewswire.com Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that, based on the compelling results observed in part one, it has initiated part two of its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in …
Next Oncology Expands Phase I Program with Virginia Cancer Specialists Partnership
Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, has entered into a joint venture with Virginia Cancer Specialists (VCS). Dr. Alex Spira of VCS sought to expand the clinic’s Phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to its Research Institute. NEXT Oncology has relationships …
Defence Therapeutics embark on next stage of breast cancer treatment development
From: healtheuropa.eu In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase 1 trial for its innovative AccuTOX breast cancer treatment. AccuTOX is one of Defence Therapeutics‘ premier candidates for effective breast cancer treatment and is comprised of the company’s cutting-edge AccumTM technology platform, which was …
Clinical Challenges: When to Start End-of-Life Care in Metastatic Breast Cancer
By: Leah Lawrence From: medpagetoday.com Breast cancer remains the second leading cause of cancer death among women in the U.S. Although treatments for metastatic breast cancer — whether a new diagnosis or recurrent disease — have improved in recent years, metastatic disease remains incurable, explained Dawn L. Hershman, MD, MS, director of breast oncology at the Herbert Irving Comprehensive Cancer …